SOPHiA GENETICS (NASDAQ:SOPH) Stock Rating Upgraded by Zacks Research

SOPHiA GENETICS (NASDAQ:SOPH) was upgraded by analysts at Zacks Research to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.

Several other equities research analysts have also weighed in on SOPH. BTIG Research restated a “buy” rating and set a $8.00 price target on shares of SOPHiA GENETICS in a research report on Monday, June 15th. HC Wainwright assumed coverage on SOPHiA GENETICS in a research report on Monday. They set a “buy” rating and a $12.00 price objective for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $9.00.

SOPHiA GENETICS Stock Performance

Shares of SOPH opened at $6.40 on Tuesday. The company has a 50-day simple moving average of $5.34 and a two-hundred day simple moving average of $5.06. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90. The firm has a market capitalization of $536.90 million, a PE ratio of -12.31 and a beta of 0.96. SOPHiA GENETICS has a one year low of $2.92 and a one year high of $6.77.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The firm had revenue of $21.69 million for the quarter, compared to analysts’ expectations of $20.40 million. On average, analysts anticipate that SOPHiA GENETICS will post -0.58 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Ross Muken sold 9,838 shares of the business’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $5.22, for a total value of $51,354.36. Following the completion of the transaction, the chief executive officer owned 670,651 shares in the company, valued at $3,500,798.22. The trade was a 1.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CTO Abhimanyu Verma sold 5,285 shares of the company’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $5.10, for a total value of $26,953.50. Following the transaction, the chief technology officer directly owned 192,171 shares in the company, valued at approximately $980,072.10. The trade was a 2.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 176,711 shares of company stock worth $959,913. 4.88% of the stock is owned by corporate insiders.

Institutional Trading of SOPHiA GENETICS

A number of institutional investors have recently made changes to their positions in SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after buying an additional 5,432,871 shares during the last quarter. Akre Capital Management LLC increased its position in SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after acquiring an additional 1,481,636 shares during the last quarter. Hodges Capital Management Inc. purchased a new stake in SOPHiA GENETICS during the first quarter valued at $2,157,000. Royce & Associates LP bought a new position in SOPHiA GENETICS in the fourth quarter valued at about $2,009,000. Finally, Sei Investments Co. bought a new position in SOPHiA GENETICS in the first quarter valued at about $1,772,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Key Headlines Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on SOPHiA GENETICS SA (NASDAQ: SOPH) and a $12 price target, signaling meaningful upside versus the current trading level. The firm’s model also forecasts the company moving toward profitability later in the decade.
• Positive Sentiment: The company’s CEO highlighted how AI could personalize patient therapies, reinforcing the growth narrative around SOPHiA GENETICS’ core technology and potentially supporting investor confidence in its long-term market opportunity. Article Title
• Neutral Sentiment: SOPHiA GENETICS said it will report second-quarter 2026 results on August 4. Upcoming earnings often keep a stock active, but this announcement is mainly a timing update rather than a business development. Article Title
• Neutral Sentiment: Zacks Research upgraded SOPHiA GENETICS to Hold, which is a small positive from a sentiment standpoint but not a strong enough signal to imply major near-term upside. Read More: Read More.
• Negative Sentiment: HC Wainwright’s estimates still show continued losses in 2026 and 2027, including full-year 2026 EPS of -$0.58 and full-year 2027 EPS of -$0.20. That highlights the company’s ongoing path-to-profitability risk, even with bullish long-term forecasts.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.